Main menu

London Calling 2023: Single-cell long-read RNA sequencing reveals complex heterogeneity in leukaemia


While introduction of novel targeted inhibitors has markedly altered the therapeutic options for treating patients with blood cancers, relapses due to acquired resistance after initial response remain a major problem. To delineate drug resistance, we applied a novel single-cell omics approach on samples from patients with progressive leukaemia who failed therapy with a targeted agent. Combining short-read with long-read targeted and whole-transcriptome sequencing identified mutations and alternative transcripts in specific sub-clones of the tumour at relapse. Thus, our single-cell integration of short-read and full-length RNA-seq provides novel insights into how complex tumour heterogeneity evolves upon acquisition of drug resistance.

Authors: Rachel Thijssen

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

ナノポア技術

ナノポアの最新ニュースを購読 リソースと発表文献 Nanopore Communityとは

Oxford Nanoporeについて

ニュース 会社沿革 持続可能性 経営陣 メディアリソース & お問い合わせ先 投資家向け パートナー向け Oxford Nanopore社で働く 現在の募集状況 営業上の情報 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag